Literature DB >> 15475446

High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence.

Gustavo Ayala1, Timothy Thompson, Guang Yang, Anna Frolov, Rile Li, Peter Scardino, Makoto Ohori, Thomas Wheeler, Wade Harper.   

Abstract

Akt is a serine-threonine-kinase that phosphorylates proteins in several pathways regulating aspects of metabolism, apoptosis, and proliferation. Akt signaling promotes proliferation and increased cell survival and is thought to play an important role in prostate cancer progression. Tissue microarrays (640 patients) with triplicate cores of non-neoplastic prostate, BPH, and index tumor were immunostained with antibody to Phospho-Akt (Ser473), digitized, and quantified. The expression index (Intensity*Percentage) was used for statistical analysis. P-Akt-1 staining was found in both the non-neoplastic and cancer tissues, predominantly in cytoplasmic locations. High level P-Akt-1 is expressed almost exclusively in cancer. By Kaplan-Meier actuarial model, high expression of P-Akt-1 in prostate cancer was predictive of a higher probability of recurrence on univariate and multivariate analysis. Akt-1 expression was an independent prognostic indicator of biochemical recurrence-free survival when Gleason 6 and 7 patients were analyzed separately. Surprisingly, a high level of P-Akt-1 expression in non-neoplastic tissues is also an independent predictor of biochemical recurrence. This suggests that some patients might have an inherent predisposition to express a high level of P-Akt-1 and, therefore, to have an adverse prognosis. We conclude that P-Akt-1 is most likely involved in the progression of prostate cancer and is an excellent biomarker for biochemical recurrence.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15475446     DOI: 10.1158/1078-0432.CCR-04-0477

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  78 in total

1.  Development of a peptide-drug conjugate for prostate cancer therapy.

Authors:  Wanyi Tai; Ravi S Shukla; Bin Qin; Benyi Li; Kun Cheng
Journal:  Mol Pharm       Date:  2011-05-03       Impact factor: 4.939

2.  Issues in collecting, processing and storing human tissues and associated information to support biomedical research.

Authors:  William E Grizzle; Walter C Bell; Katherine C Sexton
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

3.  Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE).

Authors:  Eric W Deutsch; Catherine A Ball; Jules J Berman; G Steven Bova; Alvis Brazma; Roger E Bumgarner; David Campbell; Helen C Causton; Jeffrey H Christiansen; Fabrice Daian; Delphine Dauga; Duncan R Davidson; Gregory Gimenez; Young Ah Goo; Sean Grimmond; Thorsten Henrich; Bernhard G Herrmann; Michael H Johnson; Martin Korb; Jason C Mills; Asa J Oudes; Helen E Parkinson; Laura E Pascal; Nicolas Pollet; John Quackenbush; Mirana Ramialison; Martin Ringwald; David Salgado; Susanna-Assunta Sansone; Gavin Sherlock; Christian J Stoeckert; Jason Swedlow; Ronald C Taylor; Laura Walashek; Anthony Warford; David G Wilkinson; Yi Zhou; Leonard I Zon; Alvin Y Liu; Lawrence D True
Journal:  Nat Biotechnol       Date:  2008-03       Impact factor: 54.908

4.  KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells.

Authors:  Weiya Liu; George A Vielhauer; Jeffrey M Holzbeierlein; Huiping Zhao; Suman Ghosh; Douglas Brown; Eugene Lee; Brian S J Blagg
Journal:  Mol Pharmacol       Date:  2015-05-04       Impact factor: 4.436

5.  An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation.

Authors:  Dolores Di Vizio; Matteo Morello; Federica Sotgia; Richard G Pestell; Michael R Freeman; Michael P Lisanti
Journal:  Cell Cycle       Date:  2009-08-27       Impact factor: 4.534

6.  RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancer.

Authors:  Megumi Iiizumi; Sucharita Bandyopadhyay; Sudha K Pai; Misako Watabe; Shigeru Hirota; Sadahiro Hosobe; Taisei Tsukada; Kunio Miura; Ken Saito; Eiji Furuta; Wen Liu; Fei Xing; Hiroshi Okuda; Aya Kobayashi; Kounosuke Watabe
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

7.  Biologic correlates and significance of axonogenesis in prostate cancer.

Authors:  Adriana Olar; Dandan He; Diego Florentin; Yi Ding; Gustavo Ayala
Journal:  Hum Pathol       Date:  2014-02-28       Impact factor: 3.466

8.  Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer.

Authors:  Myles C Hodgson; Long-jiang Shao; Anna Frolov; Rile Li; Leif E Peterson; Gustavo Ayala; Michael M Ittmann; Nancy L Weigel; Irina U Agoulnik
Journal:  Cancer Res       Date:  2011-01-11       Impact factor: 12.701

9.  GGAP2/PIKE-a directly activates both the Akt and nuclear factor-kappaB pathways and promotes prostate cancer progression.

Authors:  Yi Cai; Jianghua Wang; Rile Li; Gustavo Ayala; Michael Ittmann; Mingyao Liu
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

10.  Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer.

Authors:  Yi Ding; Dandan He; Diego Florentin; Anna Frolov; Sue Hilsenbeck; Michael Ittmann; Dov Kadmon; Brian Miles; David Rowley; Gustavo Ayala
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.